Table 3.
Laboratory, neuroimaging, and neurophysiological evaluation.
| Total (n = 36) | Encephalitis (n = 26) | Meningitis (n = 4) | Acute Flaccid Paralysis (n = 6) | |
|---|---|---|---|---|
| CSF profile obtained | 34 (94.4%) | 24 (92.3%) | 4 (100%) | 6 (100%) |
| Leukocyte count (cells/mm3) # |
49.5 (1–795) | 52.5 (6–795) | 40 (15–280) | 29 (1–234) |
| Protein (mg/dL) | 97.5 (37–830) | 100.5 (46–830) | 85.5 (37–136) | 81.5 (56–109) |
| Glucose (mg/dL) | 65 (43–93) | 66 (43–93) | 64 (45–89) | 64.5 (60–84) |
| Brain MRI performed | 29 (80.6%) | 22 (84.6%) | 3 (75.0%) | 4 (66.7%) |
| Any acute abnormality |
14 (48.3%) | 12 (54.6%) | 0 (0.0%) | 2 (50.0%) |
| Spine MRI performed | 13 (36.1%) | 8 (30.8%) | - | 5 (83.3%) |
| Any acute abnormality |
7 (53.9%) | 2 (25.0%) | - | 5 (100%) |
| EMG/NCS performed | 6 (16.7%) | 2 (7.7%) * | - | 4 (66.7%) |
| Demyelinating polyneuropathy |
2 (33.3%) | - | - | 2 (50.0%) |
| Predominately motor axonopathy |
4 (66.7%) | 2 (100%) | - | 2 (50.0%) |
* Both with clinical features consistent with a diagnosis of AFP; # median (range).